Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Daiichi Sankyo
Eli Lilly and Company
OHSU Knight Cancer Institute
Fate Therapeutics
Jules Bordet Institute